eFFECTOR Therapeutics, Inc. – NASDAQ:EFTRW
eFFECTOR Therapeutics stock price monthly change
eFFECTOR Therapeutics stock price quarterly change
eFFECTOR Therapeutics stock price yearly change
eFFECTOR Therapeutics key metrics
Market Cap | 2.82K |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -13.30 |
Revenue | N/A |
EBITDA | -32.85M |
Income | -34.63M |
Revenue Q/Q | N/A |
Revenue Y/Y | -95.44% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeeFFECTOR Therapeutics stock price history
eFFECTOR Therapeutics stock forecast
eFFECTOR Therapeutics financial statements
| Jun 2023 | 0 | -8.36M | |
|---|---|---|---|
| Sep 2023 | 0 | -8.30M | |
| Dec 2023 | 162K | -9.12M | -5635.19% |
| Mar 2024 | 0 | -8.83M |
| Jun 2023 | 26889000 | 24.31M | 90.42% |
|---|---|---|---|
| Sep 2023 | 20161000 | 24.12M | 119.67% |
| Dec 2023 | 20544000 | 26.33M | 128.21% |
| Mar 2024 | 27131000 | 26.30M | 96.95% |
| Jun 2023 | -8.59M | -1.57M | 14.57M |
|---|---|---|---|
| Sep 2023 | -7.75M | -1.91M | 342K |
| Dec 2023 | -5.56M | 8.94M | 6.10M |
| Mar 2024 | -7.27M | -6.32M | 14.23M |
eFFECTOR Therapeutics alternative data
| Jan 2024 | 15 |
|---|---|
| Feb 2024 | 15 |
| Mar 2024 | 15 |
| Apr 2024 | 14 |
| May 2024 | 14 |
| Jun 2024 | 14 |
| Jul 2024 | 14 |
eFFECTOR Therapeutics other data
-
When is eFFECTOR Therapeutics's next earnings date?
Unfortunately, eFFECTOR Therapeutics's (EFTRW) next earnings date is currently unknown.
-
Does eFFECTOR Therapeutics pay dividends?
No, eFFECTOR Therapeutics does not pay dividends.
-
How much money does eFFECTOR Therapeutics make?
eFFECTOR Therapeutics has a market capitalization of 2.82K.
-
What is eFFECTOR Therapeutics's stock symbol?
eFFECTOR Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "EFTRW".
-
What is eFFECTOR Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of eFFECTOR Therapeutics?
Shares of eFFECTOR Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does eFFECTOR Therapeutics have?
As Jul 2024, eFFECTOR Therapeutics employs 14 workers.
-
What is eFFECTOR Therapeutics's official website?
The official website for eFFECTOR Therapeutics is effector.com.
-
How can i contact eFFECTOR Therapeutics?
eFFECTOR Therapeutics can be reached via phone at 858 925 8215.
eFFECTOR Therapeutics company profile:
eFFECTOR Therapeutics, Inc.
effector.comNASDAQ
14
Biotechnology
Healthcare
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Solana Beach, 92075
CIK: 0001828522
ISIN: US28202V1162
CUSIP: 28202V116
